Addex Therapeutics Ltd
ADXN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $404 | $1,613 | $1,422 | $2,916 |
| % Growth | -74.9% | 13.4% | -51.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $404 | $1,613 | $1,422 | $2,916 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $435 | $943 | $7,884 | $9,014 |
| G&A Expenses | $1,675 | $2,031 | $3,262 | $7,746 |
| SG&A Expenses | $1,675 | $2,031 | $3,262 | $7,746 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,049 | $882 | $818 | $1,662 |
| Operating Expenses | $3,159 | $3,856 | $11,963 | $18,422 |
| Operating Income | -$2,755 | -$2,243 | -$10,541 | -$15,506 |
| % Margin | -681.8% | -139.1% | -741% | -531.7% |
| Other Income/Exp. Net | -$2,154 | -$257 | -$263 | $154 |
| Pre-Tax Income | -$4,909 | -$2,500 | -$10,804 | -$15,352 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $7,056 | -$10,556 | -$20,804 | -$15,352 |
| % Margin | 1,746% | -654.5% | -1,462.6% | -526.4% |
| EPS | 8.4 | -16.8 | -55.2 | -54 |
| % Growth | 150% | 69.6% | -2.2% | – |
| EPS Diluted | 8.4 | -16.8 | -55.2 | -54 |
| Weighted Avg Shares Out | 818 | 619 | 377 | 284 |
| Weighted Avg Shares Out Dil | 818 | 619 | 377 | 284 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $64 | $29 | $5 |
| Interest Expense | $4 | $22 | $49 | $63 |
| Depreciation & Amortization | $260 | $306 | $323 | $348 |
| EBITDA | -$4,646 | -$2,190 | -$10,453 | -$14,941 |
| % Margin | -1,149.6% | -135.8% | -734.9% | -512.3% |